WFUMB position paper. Incidental findings of the salivary glands

Ewa J Bialek¹, Adrian Lim², Yi Dong³, Daniela Fodor⁴, Norbert Gritzmann⁵,
Christoph F Dietrich⁶

¹Department of Diagnostic Ultrasound and Mammography, Mazovian Bródnowski Hospital, Warsaw, Poland, ²Imaging Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham, UK, ³Department of Ultrasound, Zhongshan Hospital, Fudan University, China, ⁴2nd Internal Medicine Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁵SONOSEMINARE, Vienna, Austria, ⁶Department Allgemeine Innere Medizin (DAIM) Kliniken Hirslanden Beau Site, Salem und Permanence, Bern, Switzerland

Abstract

A salivary incidentaloma (SI) stands for any focal salivary lesion, independent of size, discovered by any imaging method including ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), multimodal positron emission tomography (PET) combined with CT or MRI, or X-ray imaging, performed for another reason, in the absence of known salivary glands' disease. The article presents a detailed analysis of salivary gland diseases with the emphasis on neoplasms. It describes frequency of SIs found on imaging, their prevalence, epidemiology and clinical significance. The probability of malignancy or malignant transformation of a SI, its imaging features, recommended treatment, management and follow-up, as well as ethical issues, psychological burden, informed decision making, economical consequences and costs are discussed. The general prevalence of SIs is low, but is dramatically increasing over time, and may rise significantly in selected groups of oncologic patients. SIs most frequently turn out to be benign primary neoplasms or pseudotumors, including intraparenchymal lymph nodes. SIs detected by other imaging methods should be subsequently assessed with US. Solid SIs demand ultrasound guided fine-needle aspiration cytology (US-FNAC). Neoplasms should undergo surgery. Post-operative US follow-up is mandatory for malignant tumors and recommended for benign neoplasms.

Keywords: salivary gland; incidentaloma; guideline; neoplasia; inflammation

Introduction and definition

The World Federation for Ultrasound in Medicine and Biology (WFUMB) is dedicated to the advancement of ultrasound (US) by encouraging research, promoting international cooperation, disseminating scientific information and improving communication and understanding in the world community using ultrasound in medicine and biology [1]. WFUMB is addressing the issue of in-

cidental findings with a series of publications “Incidental imaging findings – the role of medical ultrasound” [1]. So far adrenal gland IF have been described in detail [2].

The definition of a salivary incidentaloma (SI) encompasses any focal salivary lesion, independent of size, discovered by any imaging method including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), multimodal positron emission tomography (PET) combined with CT or MRI, or X-ray imaging, performed for other reason, in the absence of known salivary glands' disease [1].

Major salivary glands are symmetrically located in the head and neck and include the parotid gland, submandibular salivary gland and sublingual salivary gland. Accessory parotid glands may be located in the cheek along the Stenon duct, the excretory duct of a parotid gland. Apart from them, there are hundreds of minor salivary glands, which are not apparent on conventional imaging,

Received 10.03.2021 Accepted 14.04.2021

Med Ultrason

2021, Vol. 23, No 3, 329-338

Corresponding author: Prof. Dr. med. Christoph F. Dietrich, MBA
Department of Internal Medicine (DAIM)
Kliniken Hirslanden Bern, Beau Site,
Salem und Permanence
Schänzlihalde 11, 3031 Bern, Switzerland
E-mail: c.f.dietrich@googlemail.com

Fig 1. Morphology in relation to frequency of benign and malignant salivary gland tumours. The scheme of major salivary glands with images representing most common neoplasms (A-C) (tumors shadowed on yellow). Percentages for the ratios of benign to malignant salivary gland neoplasms according to Bradley [5]. A – pleomorphic adenoma. B – Warthin tumor. C – adenoid cystic cancer. ECA – external carotid artery; GGM – genioglossus muscle; MA – acoustic shadow behind the mandible bone; MHM – mylohyoid muscle; PG – parotid gland; RV – retromandibular vein; SBG – submandibular salivary gland; SG – sublingual salivary gland; ST – subcutaneous tissue; T – tongue.

in the submucosa of digestive and respiratory tracts. Salivary gland tissue may be also heterotopically located in different neck structures.

Most common diseases of salivary glands are inflammation and sialolithiasis [3]. They often coexist and nearly always cause symptoms. The incidence rates of salivary tumours appear to be low, but reliable data are difficult to obtain and vary depending on the study due to a lack of studies screening large populations, due to changing histopathological classifications (newest one WHO classification dates from 2017 [(4)]), probable differential incidence rates between different populations, and improvement of imaging methods, which increases detection rates.

Estimates of salivary gland neoplasms incidence rate range from 0.4 to 13.5 per 100,000 population [5]. Most of the salivary gland neoplasms are benign (e.g., 86%) [6]. Malignant epithelial salivary gland neoplasms constitute only about 3-6% of all head and neck malignancies [5].

Salivary gland neoplasms are mainly primary and have epithelial origin. Mesenchymal (nonepithelial) neoplasms make up only 1.9-5% of all major salivary gland neoplasms [7]. Lymphomas are rarely found, are mostly non-Hodgkin and mainly due to systemic involvement, seldom as primary disease [8]. Metastases are less common, accounting for about 1% (108/10,944) of cases according to Seifert et al [9] and occur in the parenchyma or within intraparenchymal lymph nodes of the parotid or

submandibular salivary glands. The origin of metastases to salivary glands is usually from within the head and neck particularly the cutaneous malignancies squamous cell carcinoma and melanoma [9,10]. However, depending on geographic location, metastases may be found prevailing over primary parotid neoplasms, like in Australia, reaching 75% (178/232) of the patient cohort [10], which is connected with regional elevated incidence of skin cancers. Additionally, there are reports showing a rising incidence of metastases to parotid glands over recent decades in other countries such as Germany [11]. Most often (61-87%) the neoplasms occur in the parotid [6,12-14], less commonly in the submandibular salivary gland (9.5-11%) and minor salivary glands (9-28.5%) and least commonly in the sublingual salivary gland (0.5-1%) [6,12,14]. The ratios of 100:10:1:10 for site distribution of salivary gland neoplasms between parotid, submandibular, sublingual and minor salivary glands were suggested by Willis in 1953 [15] and confirmed in subsequent studies [5]. The trend of increasing frequency of tumor malignancy is inverse to the salivary glands size. The lowest rate of malignancy (9-32%) is noted in largest parotid glands, in which tumors are most commonly encountered, followed by submandibular salivary gland (25-43%) and minor salivary glands (40-62%), and up to 75-100% in sublingual salivary glands, which are fortunately the rarest sites of neoplastic growth [6,12,14,16]. Bradley [5] suggested percentages for the ratios of benign to malignant salivary gland neoplasms are 80% vs.

Fig 2. Gray scale and colour Doppler of the parotid gland (A) and submandibular gland (B) in a patient with Sjögren syndrome. Note the hypoechoic diffuse nodular lesions, hyperechoic fibros septa and increased vascularity (especially in parotid gland).

20% for parotid gland, 50% vs. 50% for submandibular salivary gland, 5% vs. 95% for sublingual salivary glands and 20% vs. 80% for minor salivary glands (fig 1). Therefore, lesions in submandibular salivary glands should be regarded as highly suspicious for malignancy and even more so in the sublingual salivary glands.

Pleomorphic adenomas (mixed tumours) and Warthin tumors (cystadenolymphomas) are the main benign neoplasms, constituting 93% [6,13,17]. The malignant salivary neoplasms are most commonly mucoepidermoid carcinoma, adenoid cystic carcinoma and adenocarcinoma not otherwise specified (NOS) accounting for about 65% of cases [6,14,17]. Salivary tumors may be multiple, of the same origin or of different type - most often Warthin tumor, occurring either synchronously or metachronously in the same salivary gland or in different ones [17]. Carcinomas of the major salivary glands are a heterogeneous group of neoplasms, ranging from low grade to aggressive malignancies, with etiologic and biological variability showing varying prevalence according to age, gender, race, and geographic location even within the same country [14,17-19].

Chronic inflammatory diseases may also present themselves as solid lesions, single or multiple. This includes granulomatous diseases such as tuberculosis or sarcoidosis and chronic sclerosing sialadenitis (Küttner tumor) [3]. Sjögren Syndrome, an autoimmune disease, may present as scattered multiple small, oval areas disseminated in both parotid and submandibular salivary glands [3] (fig 2).

Lack of high quality large prospective trials makes it difficult to define reliable evidence-based guidelines concerning the management of salivary gland incidental findings.

Chances of detecting SIs

Reports relating to SIs on CT or MRI are scarce. Parotid gland masses were incidentally detected in 2.5% (5/225) of patients undergoing CT cranial angiography [20]. On MRI (1.5T) SIs were reported only in 0.26% (2/700) of patients at the age of 73 years [21] and in 0.27% (2/730) of patients who underwent imaging of the temporomandibular joint [22]. More data is available concerning SIs on PET/CT. The frequency of incidental findings on 18F-fluorodeoxyglucose (FDG) PET/CT scans showing 18F-FDG uptake in parotid glands ranged from 0.4% to 1.73% [23-25]. Only 4 % of focal parotid incidental uptake (FPIU) turned out to be malignant in the study group of Makis et al [24] and 9.6% in the meta-analysis of Treglia et al [26]. However, Ustun et al [25] reported an incidence of parotid metastases amounting to 36.4% and similarly high values of 45% were reported by Mabray et al [27], where FPIU was frequently a manifestation of the patient's known malignancy (metastasis or lymphoma). It has to be noted that the high malignancy rates in incidental masses detected on multimodal PET imaging are mostly due to the fact that PET/CTs are performed mostly in oncologic patients, with high probability of metastases. Britt et al [28] performed a retrospective review of 771 patients who underwent parotidectomy. Within the group of parotid masses found incidentally on CT, MRI or PET/CT, carried out for an unrelated indication, the overall rate of malignant neoplasms was 6% (4/67). In the group where masses were identified in symptomatic patients owing to pain, facial nerve dysfunction, palpable mass or other reasons, the frequency of malignant neoplasm was higher, 32.7% (230/704) [28].

A dramatic increase in the prevalence of parotid incidentalomas (PIs) over time detected on imaging was identified by Britt et al [28]. Their study reports a 155% increase over a 20-year study period (1994-2013), where 4% of all parotidectomies were performed for PIs during the first decade and 10.2% during the second decade.

The percentage of PIs that were malignant, detected by various imaging methods, was 5% (95%CI 2, 10) [29]. The histology of the SIs found on CT, MRI, PET/CT or PET/MRI should be confirmed using fine-needle aspiration cytology or core biopsy guided by US [30,31].

On US, SIs may also be detected during scans performed for thyroid, lymph nodes or carotid arteries assessment. Salivary glands screened by Onda et al during thyroid US revealed abnormal incidental findings in about 4% of patients (36/908). This included atrophy/swelling, unclear boundaries of the gland or hypervascularity in addition to internal heterogeneity, as well as tumors [32]. Tumors underwent fine needle aspiration cytology

Fig 3. Normal intraparenchymal lymph nodes in the parotid gland, which should not be mistaken for a pathologic lesion: A) raw gray-scale images; B) lymph nodes parenchyma marked with yellow; border of the parotid gland marked with a dashed line; PG – parotid gland; ST – subcutaneous tissue; C) color Doppler images showing hilar or central branching lymph node vessels – arrows.

(FNAC), while other abnormalities were evaluated with further blood tests and imaging studies [32].

Specific categories of incidental findings in salivary glands are typically calcification or stones/sialoliths [33]. Calcifications were reported in parotid glands in 4% of noncontrast head CT and revealed association with HIV, alcoholism, chronic kidney disease, autoimmune disease and elevated alkaline phosphatase [34]. From 350 incidental findings identified in 999 cone-beam CT of the head and neck, submandibular gland stones constituted 0.8% [35]. Incidental reports have also been reported from the sublingual gland revealing multiple sialoliths on orthopantomograms [36]. In cases of salivary glands calcification/stones detected by an imaging method which does not provide visualization of the gland parenchyma and excretory ducts, US should be taken in consideration as it permits differentiation between true stones, phleboliths or tumor calcification. A stone may also be incidentally discovered on US performed for other reasons. In

the Sigismund et al study, US allowed for detection of stones not causing symptoms in 2.6% (61/2,322) of patients with sialolithiasis [33].

It is important not to mistake intraparenchymal lymph nodes, which are intrinsic structures especially in parotid glands parenchyma, from true focal abnormalities. This may be challenging, especially for inexperienced sonographers (fig 3) and in indeterminate cases, US-FNAC should be performed.

In summary, allowing for the difference amongst all the reported studies, the prevalence of SIs on imaging ranges from 0.26% to about 10%, with the rate of malignancy of 4% rising to 45% in SIs detected on FDG PET/CT studies. One should be aware that these studies having PET/CT will be a highly selected group of patients, likely with known malignancy.

Salivary gland neoplasm

Prevalence, epidemiology

The etiology of salivary gland neoplasm in most patients is unknown [37] but their occurrence is associated with high and low-dose irradiation, explosion to silica dust, nickel, rubber manufacturing, using kerosene as a cooking fuel, high serum cholesterol, low vitamin intake and low intake of dark yellow vegetables [38]. In Epstein-Barr virus infections, a higher incidence of undifferentiated carcinoma, Warthin's tumor and salivary T-cell lymphoma was reported in AIDS patients [38]. Warthin tumors are strongly associated with smoking [38]. Recent studies revealed specific chromosomal abnormalities and gene mutations connected with benign and malignant salivary neoplasms [38]. It is hoped that these genetic markers may in future be useful in salivary glands' neoplasms diagnosis, therapy and prognosis [38,39].

Clinical significance

Clinical significance of SIs depends on the method of their detection. The most significant lesions seem to be tumors detected on multimodal PET imaging showing FDG uptake but these examinations were typically performed in patients with a known malignancy for staging [27]. SIs detected by other imaging modalities are most likely benign primary neoplasms or pseudotumors, including intraparenchymal lymph nodes.

Salivary glands and their incidentalomas

Two of the most common benign salivary gland neoplasms may undergo malignant transformation.

Pleomorphic adenomas (PA), are the most common neoplasms of salivary glands and may undergo malignant transformation to carcinoma in about 0.15 - 2.86% of new cases, or in 3.2-3.3 % of recurrent cases (as re-

Fig 4. These lesions all have similar grey-scale ultrasound appearances but are of different aetiologies: A) small pleomorphic adenoma; B) small mucoepidermoid cancer; C) Small reactive lymph node without apparent hilum. All presented masses demand further work-up by means of US-guided FNAC.

ported Valstar et al from analysis of 3.506 cases of PA from Dutch pathology registry [40] and Andreassen et al from analysis of 5.497 patients from The Danish Pathology Data Bank [41]. Recurrence of PA are usually multifocal and encountered in about 6.7%, especially after incomplete resection of a PA, with a median time to first recurrence of 7 years [40]. The rate of re-recurrence of PA may reach 46.6%, posing a significant problem for these patients [41]. Warthin tumors may undergo malignant transformation much less often than PAs, in about 0.5% of cases [42]. However, in a retrospective histological evaluation by Alnoor et al the prevalence rate of lymphoid neoplasia in Warthin tumors was found higher, 3.4%: with overt lymphoma in 2.2%, and in situ follicular neoplasia of 1.1% [43]. An interesting issue is the possibility of high-grade transformation within salivary gland carcinoma, usually previously low grade, which implies increased aggressiveness and poorer prognosis. The concept has been introduced in the latest 4th edition of WHO classification of tumors [4].

Imaging features including echo texture

Low-grade salivary malignancies may show slow growth and no typical malignant features, mimicking benign tumors [3], especially when less than 20 mm in size (fig 4). Some small metastases may show pseudo-benign imaging features. This poses a serious pitfall for imaging specialists where accurate differentiation of benign from malignant salivary lesions in conventional imaging is usually not possible.

Obviously, in case of aggressive or high-grade tumors irregular shape, spiculated or ill-defined margins, infiltration of surrounding tissues, inhomogeneous structure and the presence of abnormal lymph nodes malignancy is likely [3,19,44] (fig 1, fig 5). Nevertheless, the lack of above mentioned imaging features does not completely exclude malignancy. In the study by Borsetto et al only 33.3% of all confirmed malignant tumors had characteristic imaging features of malignancy [45]. The most commonly occurring benign salivary neoplasms, pleomorphic adenoma and Warthin tumors, have a few typical but not pathognomic imaging features. Pleomorphic adenomas (PAs) often have lobulated, polycyclic margins and may be inhomogeneous [3,46], which reflects their complex histopathological nature, with epithelial and myoepithelial cells arranged in mucoid, myxoid or chondroid background, sometimes with osseous metaplasia or lipomatous differentiation [47] (fig 1, fig 6). PAs are usually poorly vascularized but have varying vascular density [3,46]. Polycyclic shape is a poor discriminator of benign and malignant salivary neoplasms, where either may present with any shape [3]. In Warthin tumors (WTs) anechoic spaces reflecting their histopathological composition are often encountered (up to 93% by Shimizu et al) [48]. The stroma of a WT is composed of dense lymphoid tissue with cystic areas lined by a bilayered epithelium, which may present papillae [47]. However,

Fig 5. Mucoepidermoid carcinoma of the parotid gland, grey scale (A) and Color Doppler (B) (irregular shape, ill defined margins, inhomogenous appearance and hypervascularized tumor) associated with round, hypoechoic and without hilum regional metastatic lymphnode (C).

Fig 6. Pleomorphic adenoma, grey scale (A) and color Doppler (B) with lobulated, polycyclic margins, slightly inhomogeneous and moderate vascularised

Fig 7. Warthin tumour, grey scale (A) and colour Doppler (B): inhomogenous structure, with fluid component (cystic areas) and hypervascularisation (courtesy Dr Manuela Lenghel)

other benign and malignant salivary neoplasms may also present with internal fluid-like components [46,49]. Most WTs are very well vascularized [3] (fig 7).

US contrast agents and elastography

Relatively newer US techniques include ultrasound contrast agents and elastography. Neither of them has been revolutionary in characterising salivary gland neoplasms. Application of microbubble contrast allows for additional assessment of microvasculature of tumors and contrast kinetics, but present studies are limited in number and are based on insufficiently large and selected populations of patients, which does not allow for drawing far-reaching conclusions [50]. According to Bhatia et al, elastography appears suboptimal for detection of malignancy in the salivary glands because of overlapping elastic properties between benign and malignant lesions [51]. Similar conclusions are drawn from a meta-analysis concerning parotid lesions, showing heterogeneous study results and indicating a limited value of elastography in differential diagnosis between malignant and benign tumors, which may be due to their histopathological variety [52]. However, higher stiffness in shear wave elastography (SWE) may indicate a parotid lymphoma in primary Sjögren Syndrome, promising the potential use of SWE for early diagnosis, biopsy guidance and possibly treatment monitoring [53].

Contrast-enhanced and nuclear medicine techniques

Like US, conventional CT and MRI even with additional post-contrast imaging does not allow for a reliable differentiation between malignant and benign salivary neoplasms because of a significant overlap in morphological features between the two groups. Moreover, these two latter techniques are much more expensive, may have contraindications, are less quickly available, CT utilizes ionizing radiation and CT/MRI contrasts have potential side-effects. Irregular margins and invasion of local structures on CT/MRI detected lesions, similar

to US, suggests malignancy [19,44]. However, these features may not be present, especially in lower-grade or smaller sized malignancies. On MRI, an additional feature suggesting malignancy is hypointensity on T2-weighted images [19,44]. Newer MRI sequences bring additional values and can improve diagnostic accuracy, however do not allow for definite detection of tumor malignancy and are time consuming. High diffusion restriction on diffusion-weighted-imaging (DWI) corresponding with its derived low apparent diffusion coefficient (ADC) values and high intratumoral susceptibility signal intensity (ITSS) on susceptibility-weighted imaging (SWI), the latter an indirect indicator of angiogenesis, may indicate malignancy [54]. However, Warthin tumors may have confusing features, showing even higher diffusion restriction than malignant tumors and similar ITSS [54]. Low and progressive wash-in on dynamic contrast-enhanced perfusion-weighted imaging (DCE-PwI) in association with high ADC values were observed only in benign neoplasms [55]. But Warthin tumors ADC values and contrast enhancement curve patterns overlapped with lymphomas and malignant tumors [55]. Recently introduced amide proton transfer-weighted (APTw) MRI can be useful in discriminating malignant from benign tumors of the major salivary glands, where APTw-signals in malignant tumors are significantly higher than in benign ones [56]. However, this needs confirmation in further multicentre studies. It is not possible to differentiate benign from malignant salivary gland tumors based on 18F-FDG PET/CT, as benign neoplasms may show FDG uptake [24]. An interesting fact is the specific character of Warthin tumors, which are commonly hot on 99mTc scintigraphy unlike the majority of other benign and malignant salivary neoplasms [57]. This may be used as an adjunct to the decision making process when suspected Warthin tumors are managed conservatively with clinical observation in patients who have significant comorbidities, refuse surgery or are of advanced age [58].

Combined imaging criteria

In cases of sizable salivary lesions or tumors in the deep parotid lobe or in case of malignant tumor, where there is a need for assessment of the deep lying lymph nodes (e.g. at the base of the skull, retropharyngeal, retrotracheal), inaccessible by US, preoperative MR or CT is indicated to determine patient management or for surgical planning [19]. In case of advanced and high-grade malignant tumors, a staging chest CT is recommended [19]. Kikuchi et al suggested that the diagnostic algorithm of parotid tumors begin with DWI MRI in order to exclude pleomorphic adenomas based on high ADC values, with subsequent ^{99m}Tc scintigraphy to exclude Warthin tumors, leaving core needle biopsy (CNB) to be performed in the remaining cases [57]. However, such an algorithm appears far more expensive than US-FNAC and US follow-up.

Image (US) - guided biopsy

The procedure of cell sampling for cytology assessment by aspiration with use of a needle is described using two interchangeable terms: fine needle aspiration biopsy (FNAB) and fine needle aspiration cytology (FNAC). Recommendations, including those issued by The Education Committee of The American Head and Neck Society (AHNS) within the series “Do you know your guidelines”, United Kingdom National Multidisciplinary Guidelines and The National Comprehensive Cancer Network (NCCN) Guidelines, advocate US guided FNAC (US-FNAC) as a standard first-line procedure for all salivary tumors [19,59,60], whether solid or cystic [49]. US-FNAC is simple in technique, almost painless, with rare complications, fast, minimally invasive, easily available and is cost-effective. The of accuracy FNAB will vary depending on the experience of the center expressed by the amount of examined and treated patients, sampling methods, the person who is performing the procedure: a pathologist, a radiologist or a clinician, and they are better when FNAB is monitored with US [61,62].

To improve accuracy, FNAC is best performed at a high-volume case load center [63] and reported by an expert histopathologist [59]. The Education Committee of the AHNS grants permission to perform FNAB without US guidance if the lesion is easily accessed anatomically or palpable [19], however, US guidance is advisable where available. The drawback of FNAC is its moderate to low sensitivity, with varied reported percentages, 78%; with 95%CI 74%, 82% (n=5647 patients) [61], as low as 58-59% (n=371 FNAC; n=554 FNAC) [64,65] or as high as 82% (n=996 patients) [66]. One of the reasons, as with imaging, are the intrinsic properties of low-grade malignancies, with no significant cell atypia possible to be recognized basing only on their morphology [64]. The

specificity and negative predictive value (NPV) of FNAC in differentiating malignant from benign salivary lesions is high, but with large diversity in reported percentages [61]. In a meta-analysis of 5647 patients, specificity was 98% (95%CI 97%, 98%) [61] and other studies have cited 99% [64]. NPV for determining parotid malignancy was reported ranging between 91 and 95% [63-65,67]. False negative results are unfortunately possible in FNAC; therefore, patients with results negative for malignancy should be monitored with US. In case of rapid enlargement or suspicious US features, US-FNAC should be repeated. Core needle biopsy (CNB) is reported to have better sensitivity than FNAB, reaching 88.2-89.6% [64,68]. Nevertheless, CNB requires local anesthesia, is regarded more invasive and potentially exposes the patient for the risk of facial nerve injury, seeding of tumor cells, hematoma or inflammation, therefore it should be limited to cases where the definite diagnosis is not possible with FNAC or when lymphoma is suspected [69,70].

Follow-up

There are no established guidelines for the follow-up post-treatment of malignant salivary neoplasms. The Committee of the AHNS [19] suggests individual adjustment of the scheme of monitoring and present conventional schedule with repeated clinical examinations and history (“every 1-3 months in the first year, every 2-6 months in the second year, every 4-8 months up to five years and later each year”) and imaging after 3 months with the same modality as before treatment. Special attention is advocated for adenoid cystic carcinoma where regular neck imaging and consideration of annual chest CT to enable early detection of recurrence or metastases [19]. We recommend regular US-follow up post resection of not only malignant, but also of benign, salivary neoplasms. The latter, for example, in pleomorphic adenomas frequently recur and in the case of Warthin tumors, there is possible metachronous appearance.

Surgery and other treatment options

The general first-line treatment option for primary salivary neoplasms is surgery [19,59] apart from lymphomas, which are treated with chemotherapy [71]. For submandibular salivary glands, total excision of the gland is performed, while for parotid glands, the extent of surgery depends on the size, location and the nature of the tumor. This may include extracapsular dissection, partial superficial parotidectomy and superficial parotidectomy [45,72]. Elective neck lymph nodes dissection is considered for all malignant tumors but is mandatory for high-grade and high-stage neoplasms. A therapeutic neck dissection is mandatory when clinically positive lymph node metastases are present [19]. In some cases, adjuvant radiotherapy (RT) or chemoradiation therapy

is recommended after surgery with malignant tumors [19,59]. Radiotherapy however may cause salivary gland hypofunction and xerostomia which will impair the patient's quality of life [73]. In cases where occasional, conservative management is chosen of an incidental solid salivary mass, US follow-up is mandatory, with repeated US guided FNAC when suspicious ultrasound features or when rapid growth are observed.

Clinical scenarios and role of ultrasound

Detection of SI by ultrasound

The inclusion of salivary gland screening in the protocol of US examinations of other head and neck structures depends on the available time, national regulations and meticulous examination of the sonologist. In case of detection of a SI by US, the next step is to suggest US-FNAC/FNAB and US follow up, depending on the cytopathology result, as well as a consultation by an otorhinolaryngology specialist.

Ethical issues, psychological burden

The general public are generally less aware of the spectrum of salivary glands diseases in comparison with pathologies of other human organs. They usually do not connect salivary glands with cancer or other neoplastic diseases, as they do in case of breast, prostate, lungs, liver or brain. Some are even not conscious of having such glands.

Therefore, SIs suggested for control imaging or FNAB usually do not concern people very much.

Informed decision making

When a SI FNAC result suggests primary salivary malignancy, there are usually no reasons from the patient to refuse surgery, however that may depend on life expectancy. If a detected mass is relatively small and FNAC results are benign, US follow-up should be recommended after informing the patient about possible false negative cytology result and low, but potential risk of malignant transformation. The increased risk of post-operative complications when operating on a larger neoplasm detected later, should also be discussed.

Economic factors

US suggested for follow up or FNAB verification of a SI is relatively cheap. FNAB in superficial organs usually has no complications or only minor ones. Therefore, the costs of observing or verifying an SI are relatively low, especially taking into consideration the low prevalence of SIs. However, when malignancy is suggested by FNAB, further imaging of a SI is needed: CT or MRI. Nevertheless, early detection leads to treatment at an earlier stage, which is probably more cost-effective as well for the individual patient, as for the medical system.

Acknowledgement: The authors acknowledge excellent advice from Professor Anil Ahuja

Conflict of interest: none

References

1. Dietrich CF, Westerway S, Nolsoe C, Kim S, Jenssen C. Commentary on the World Federation for Ultrasound in Medicine and Biology Project "Incidental Findings". *Ultrasound Med Biol* 2020;46:1815-1820.
2. Dietrich CF, Correias JM, Dong Y, Nolsoe C, Westerway SC, Jenssen C. WFUMB position paper on the management incidental findings: adrenal incidentaloma. *Ultrasonography* 2020;39:11-21.
3. Bialek EJ, Jakubowski W, Zajkowski P, Szopinski KT, Osowski A. US of the major salivary glands: anatomy and spatial relationships, pathologic conditions, and pitfalls. *Radiographics* 2006;26:745-763.
4. El-Naggar AK CJ, Grandis JR, Takata T, Slootweg PJ. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. 4th ed. In: International Agency for Research on Cancer (IARC); 2017; Lyon; 2017.
5. Bradley PJ. Frequency and Histopathology by Site, Major Pathologies, Symptoms and Signs of Salivary Gland Neoplasms. *Adv Otorhinolaryngol* 2016;78:9-16.
6. Bradley PJ, McGurk M. Incidence of salivary gland neoplasms in a defined UK population. *Br J Oral Maxillofac Surg* 2013;51:399-403.
7. Rajendran A SB. Shafer's Textbook of Oral Pathology. 7th ed. Elsevier Health Sciences 2014.
8. Dispenza F, Cicero G, Mortellaro G, Marchese D, Kulamara G, Dispenza C. Primary non-Hodgkins lymphoma of the parotid gland. *Braz J Otorhinolaryngol* 2011;77:639-644.
9. Seifert G, Hennings K, Caselitz J. Metastatic tumors to the parotid and submandibular glands--analysis and differential diagnosis of 108 cases. *Pathol Res Pract* 1986;181:684-692.
10. Bron LP, Traynor SJ, McNeil EB, O'Brien CJ. Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. *Laryngoscope* 2003;113:1070-1075.
11. Franzen A, Buchali A, Lieder A. The rising incidence of parotid metastases: our experience from four decades of parotid gland surgery. *Acta Otorhinolaryngol Ital* 2017;37:264-269.
12. Li LJ, Li Y, Wen YM, Liu H, Zhao HW. Clinical analysis of salivary gland tumor cases in West China in past 50 years. *Oral Oncol* 2008;44:187-192.
13. Stryjewska-Makuch G, Kolebacz B, Janik MA, Wolnik A. Increase in the incidence of parotid gland tumors in the years 2005-2014. *Otolaryngol Pol* 2017;71:29-34.
14. Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. *Int J Oral Maxillofac Surg* 2010;39:235-242.
15. RA Willis. Epithelial tumors of the salivary glands. In: *Pathology of Tumors*, 2nd ed. Butterworth, London; 1953:320-348.

16. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. *Head Neck Surg* 1986;8:177-184.
17. Bello IO, Salo T, Dayan D, et al. Epithelial salivary gland tumors in two distant geographical locations, Finland (Helsinki and Oulu) and Israel (Tel Aviv): a 10-year retrospective comparative study of 2,218 cases. *Head Neck Pathol* 2012;6:224-231.
18. Boukheris H, Curtis RE, Land CE, Dores GM. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. *Cancer Epidemiol Biomarkers Prev* 2009;18:2899-2906.
19. Mantravadi AV, Moore MG, Rassekh CH. AHNS series: Do you know your guidelines? Diagnosis and management of salivary gland tumors. *Head Neck* 2019;41:269-280.
20. Kanesa-Thanan R, Cox M, Patel M, et al. Actionable vascular and other incidental findings on CTA in patients undergoing acute stroke intervention. *Neuroradiol J* 2018;31:572-577.
21. Sandeman EM, Hernandez Mdel C, Morris Z, et al. Incidental findings on brain MR imaging in older community-dwelling subjects are common but serious medical consequences are rare: a cohort study. *PLoS One* 2013;8:e71467.
22. Makdissi J, Pawar RR, Radon M, Holmes SB. Incidental findings on MRI of the temporomandibular joint. *Dentomaxillofac Radiol* 2013;42:20130175.
23. Barbara RR, Pawaroo D, Beadmoore C, Hujairi N, Newman D. Parotid incidentalomas on positron emission tomography: what is their clinical significance? *Nucl Med Commun* 2019;40:264-269.
24. Makis W, Ciarallo A, Gotra A. Clinical significance of parotid gland incidentalomas on (18)F-FDG PET/CT. *Clin Imaging* 2015;39:667-671.
25. Ustun F, Tastekin E, Tas A, Altun GD. The Clinical Significance of Incidental Parotid Uptake in a PET/CT Study: A Diagnostic Algorithm. *Curr Med Imaging Rev* 2019;15:326-333.
26. Treglia G, Bertagna F, Sadeghi R, Muoio B, Giovannella L. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: a meta-analysis. *Eur Arch Otorhinolaryngol* 2015;272:3617-3626.
27. Mabray MC, Behr SC, Naeger DM, Flavell RR, Glastonbury CM. Predictors of pathologic outcome of focal FDG uptake in the parotid gland identified on whole-body FDG PET imaging. *Clin Imaging* 2015;39:1073-1079.
28. Britt CJ, Stein AP, Patel PN, Harari PM, Hartig GK. Incidental Parotid Neoplasms: Pathology and Prevalence. *Otolaryngol Head Neck Surg* 2015;153:566-568.
29. O'Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA. Prevalence and outcomes of incidental imaging findings: umbrella review. *BMJ* 2018;361:k2387.
30. Halder S, Sinnott JD, Tekeli KM, Turner SS, Howlett DC. Biopsy of parotid masses: Review of current techniques. *World J Radiol* 2016;8:501-505.
31. Lanisnik B, Levart P, Cizmarevic B, Svagan M. Surgeon-performed ultrasound with fine-needle aspiration biopsy for the diagnosis of parotid gland tumors. *Head Neck* 2021. doi:10.1002/hed.26630.
32. Onda K, Fukuhara T, Matsuda E, et al. Impact of Screening for Salivary Gland by Ultrasonography. *Yonago Acta Med* 2020;63:42-46.
33. Sigismund PE, Zenk J, Koch M, Schapfer M, Rudes M, Iro H. Nearly 3,000 salivary stones: some clinical and epidemiologic aspects. *Laryngoscope* 2015;125:1879-1882.
34. Buch K, Nadgir RN, Fujita A, Tannenbaum AD, Ozonoff A, Sakai O. Clinical associations of incidentally detected parotid gland calcification on CT. *Laryngoscope* 2015;125:1360-1365.
35. Togan B, Gander T, Lanzer M, Martin R, Lubbers HT. Incidence and frequency of nondental incidental findings on cone-beam computed tomography. *J Craniomaxillofac Surg* 2016;44:1373-1380.
36. Pace C, Ward S. Incidental finding of sialolithiasis in the sublingual gland: a diagnostic dilemma. *Dent Update* 2011;38:704-705.
37. Lin HH, Limesand KH, Ann DK. Current State of Knowledge on Salivary Gland Cancers. *Crit Rev Oncol* 2018;23:139-151.
38. Gallo O, Franchi A. Aetiology and molecular changes in salivary gland tumours. In: McGurk M, Combes J. (Eds.). *Controversies in the Management of Salivary Gland Disease*. 2nd Edition. Oxford University Press; Oxford, 2012.
39. Matse JH, Yoshizawa J, Wang X, et al. Human Salivary Micro-RNA in Patients with Parotid Salivary Gland Neoplasms. *PLoS One* 2015;10:e0142264.
40. Valstar MH, de Ridder M, van den Broek EC, et al. Salivary gland pleomorphic adenoma in the Netherlands: A nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. *Oral Oncol* 2017;66:93-99.
41. Andreasen S, Therkildsen MH, Bjorndal K, Homoe P. Pleomorphic adenoma of the parotid gland 1985-2010: A Danish nationwide study of incidence, recurrence rate, and malignant transformation. *Head Neck* 2016;38 Suppl 1:E1364-E1369.
42. Seifert G. Carcinoma in pre-existing Warthin tumors (cystadenolymphoma) of the parotid gland. Classification, pathogenesis and differential diagnosis. *Pathologie* 1997;18:359-367.
43. Alnoor FNU, Gandhi JS, Stein MK, Solares J, Gradowski JF. Prevalence of Lymphoid Neoplasia in a Retrospective Analysis of Warthin Tumor: A Single Institution Experience. *Head Neck Pathol* 2020;14:944-950.
44. Elmokadem AH, Abdel Khalek AM, Abdel Wahab RM, et al. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging for Differentiation Between Parotid Neoplasms. *Can Assoc Radiol J* 2019;70:264-272.
45. Borsetto D, Fussey JM, Cazzador D, et al. The diagnostic value of cytology in parotid Warthin's tumors: international multicenter series. *Head Neck* 2020;42:522-529.
46. Bialek EJ, Jakubowski W, Karpinska G. Role of ultrasonography in diagnosis and differentiation of pleomorphic

- adenomas: work in progress. *Arch Otolaryngol Head Neck Surg* 2003;129:929-933.
47. Rousseau A, Badoual C. Head, neck: Salivary gland tumors: an overview. *Atlas Genet Cytogenet Oncol Haematol* 2011;15:533-541.
  48. Shimizu M, Ussmuller J, Hartwein J, Donath K, Kinukawa N. Statistical study for sonographic differential diagnosis of tumorous lesions in the parotid gland. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;88:226-233.
  49. Pantanowitz L, Thompson LDR, Rossi ED. Diagnostic Approach to Fine Needle Aspirations of Cystic Lesions of the Salivary Gland. *Head Neck Pathol* 2018;12:548-561.
  50. David E, Cantisani V, De Vincentiis M, et al. Contrast-enhanced ultrasound in the evaluation of parotid gland lesions: an update of the literature. *Ultrasound* 2016;24:104-110.
  51. Bhatia KS, Lee YY, Yuen EH, Ahuja AT. Ultrasound elastography in the head and neck. Part II. Accuracy for malignancy. *Cancer Imaging* 2013;13:260-276.
  52. Zhang YF, Li H, Wang XM, Cai YF. Sonoelastography for differential diagnosis between malignant and benign parotid lesions: a meta-analysis. *Eur Radiol* 2019;29:725-735.
  53. Badarinza M, Serban O, Maghear L, et al. Shear wave elastography as a new method to identify parotid lymphoma in primary Sjogren Syndrome patients: an observational study. *Rheumatol Int* 2020;40:1275-1281.
  54. Jiang JS, Zhu LN, Chen W, et al. Added value of susceptibility-weighted imaging to diffusion-weighted imaging in the characterization of parotid gland tumors. *Eur Arch Otorhinolaryngol* 2020;277:2839-2846.
  55. Pietragalla M, Nardi C, Bonasera L, et al. The role of diffusion-weighted and dynamic contrast enhancement perfusion-weighted imaging in the evaluation of salivary glands neoplasms. *Radiol Med* 2020;125:851-863.
  56. Bae YJ, Choi BS, Jeong WJ, et al. Amide Proton Transfer-weighted MRI in the Diagnosis of Major Salivary Gland Tumors. *Sci Rep* 2019;9:8349.
  57. Kikuchi M, Koyasu S, Shinohara S, Imai Y, Hino M, Naito Y. Preoperative Diagnostic Strategy for Parotid Gland Tumors Using Diffusion-Weighted MRI and Technetium-99m Perchnetate Scintigraphy: A Prospective Study. *PLoS One* 2016;11:e0148973.
  58. Nakahara T, Suzuki T, Hashimoto J, et al. Role of salivary gland scintigraphy with Tc-99m pertechnetate in determining treatment of solitary parotid gland tumors: a retrospective study. *Clin Nucl Med* 2007;32:363-366.
  59. Sood S, McGurk M, Vaz F. Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. *J Laryngol Otol* 2016;130:S142-S149.
  60. Wierzbicka M, Napierala J. Updated National Comprehensive Cancer Network guidelines for treatment of head and neck cancers 2010-2017. *Otolaryngol Pol* 2017;71:1-6.
  61. Liu CC, Jethwa AR, Khariwala SS, Johnson J, Shin JJ. Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg* 2016;154:9-23.
  62. Zbaren P, Triantafyllou A, Devaney KO, et al. Preoperative diagnostic of parotid gland neoplasms: fine-needle aspiration cytology or core needle biopsy? *Eur Arch Otorhinolaryngol* 2018;275:2609-2613.
  63. Feinstein AJ, Alonso J, Yang SE, St John M. Diagnostic Accuracy of Fine-Needle Aspiration for Parotid and Submandibular Gland Lesions. *Otolaryngol Head Neck Surg* 2016;155:431-436.
  64. Song IH, Song JS, Sung CO, et al. Accuracy of Core Needle Biopsy Versus Fine Needle Aspiration Cytology for Diagnosing Salivary Gland Tumors. *J Pathol Transl Med* 2015;49:136-143.
  65. Galli A, Tulli M, Giordano L, et al. Fine needle aspiration cytology for parotid neoplasms: risk of malignancy through inconclusive results and lower grade tumors. *Eur Arch Otorhinolaryngol* 2020;277:841-851.
  66. Suzuki M, Kawata R, Higashino M, et al. Values of fine-needle aspiration cytology of parotid gland tumors: A review of 996 cases at a single institution. *Head Neck* 2019;41:358-365.
  67. Eytan DF, Yin LX, Maleki Z, et al. Utility of preoperative fine needle aspiration in parotid lesions. *Laryngoscope* 2018;128:398-402.
  68. Del Cura JL, Coronado G, Zabala R, Korta I, Lopez I. Accuracy and effectiveness of ultrasound-guided core-needle biopsy in the diagnosis of focal lesions in the salivary glands. *Eur Radiol* 2018;28:2934-2941.
  69. Baer AN, Grader-Beck T, Antiochos B, Birnbaum J, Fradin JM. Ultrasound-guided biopsy of suspected salivary gland lymphoma in Sjogren's syndrome. *Arthritis Care Res (Hoboken)* 2020. doi:10.1002/acr.24203.
  70. Romano EB, Wagner JM, Alleman AM, Zhao L, Conrad RD, Krempel GA. Fine-needle aspiration with selective use of core needle biopsy of major salivary gland tumors. *Laryngoscope* 2017;127:2522-2527.
  71. Cabecadas J, Martinez D, Andreasen S, et al. Lymphomas of the head and neck region: an update. *Virchows Arch* 2019;474:649-665.
  72. Li C, Matthies L, Hou X, Knipfer C, Gosau M, Friedrich RE. A meta-analysis of the pros and cons of partial superficial parotidectomy versus superficial parotidectomy for the treatment of benign parotid neoplasms. *J Craniomaxillofac Surg* 2020;48:590-598.
  73. Jensen SB, Vissink A, Limesand KH, Reyland ME. Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients. *J Natl Cancer Inst Monogr* 2019;2019:lgz016.